Research programme: anticancer therapeutics - NanoCarrier/Kirin

Drug Profile

Research programme: anticancer therapeutics - NanoCarrier/Kirin

Latest Information Update: 17 Jan 2007

Price : $50

At a glance

  • Originator Kirin Brewery; NanoCarrier
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 17 Jan 2007 No development reported - Preclinical for Cancer in Japan (unspecified route)
  • 07 Apr 2003 Preclinical trials in Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top